Genital Human Papillomavirus: DNA based Epidemiology. Anil K.Chaturvedi, D.V.M., M.P.H. Human Papillomavirus (HPV). Papillomaviridae Most common viral STD Double stranded DNA virus ~8 Kb Entire DNA sequence known. HPV genome. Classification of HPV types.
Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.
Anil K.Chaturvedi, D.V.M., M.P.H
*Tyring SK, American journal of medicine, 1997
Tindle RW, Nature Reviews, Cancer, Vol2: Jan2002
Herald Zur Hausen, Nature Reviews, Cancer Volume 2:5; May; 2002.
Koutsky, LA, American Journal of Medicine, May 5, Vol 102, 1997.
SEER data and Statistics, CDC.
See cellular changes caused by the virus:
Pap smear screening
Directly detect the virus:
DNA hybridization or PCR*
Detect previous infection:
Detection of antibody against HPV*
* Done in the Hagensee Laboratory
Rates of progression
Herald Zur Hausen, Nature Reviews, Cancer Volume 2:5; May; 2002
Anil K Chaturvedi1, Jeanne Dumestre2, Ann M. Gaffga2, Kristina M. Mire,2Rebecca A.Clark2, Patricia S.Braly3, Kathleen Dunlap3,Patricia J. Kissinger1, and Michael E. Hagensee2
Cervical swabs and
36 LR (52.9%)
232 HR (61.7%)
95 HIV+ (56.8%)
DNA from cervical swabsPolymerase chain reaction using PGMy09/11 consensus primer system reverse line hybridization (Roche molecular systems, CA)
Roche molecular systems Inc., Alameda, CA.
[34.51 (SD=9.08) vs. 26.72 (SD=8,93) ] p<0.05
* P for trend <0.001
CD4 cell counts (<200 vs.>200) Profiles
HIV-RNA viral loads
0.93(0.34, 2.58)HIV+ sub-set analyses, N=167, multivariate
Palefsky JM, Cancer epi Biomarkers and Prev, 1997.
Anil K Chaturvedi1, Jeanne Dumestre2, Issac V.Snowhite, Joeli A. Brinkman,2Rebecca A.Clark2, Patricia S.Braly3, Kathleen Dunlap3,Patricia J. Kissinger1, and Michael E. Hagensee2
1.Characterize prevalence of multiple HPV infections in HIV+ and HIV- women
2. Does the risk of cytologic abnormalities differ by oncogenic-non-oncogenic combination categories
3. Compartmentalize impact of mutiple HPV infections in a multi-factorial scenario
Pap data available
AF= Pr (D)- Pr (Disease/ not exposed)
P-for trend <0.001
Multiple high-risk types- (OR=2.08, 1.11-3.89) and LR-HR combinations ( 2.40, 1.28-4.52) risk of cytologic abnormalities
Co-variates: HIV: yes, no&Age : <25 years and >=25 years
3. Intercept, HIV-, Single HPV (D1), Multiple HPV (D2) and age < 25
4. Intercept, D1, D2, HIV+, age <25
*Appropriately adjusted based on comparison models
Dr.Hagensee and Dr.Kissinger (Mentors), Dr.Myer’s
Hagensee Laboratory : Basic
Isaac Snowhite Joeli Brinkman Jennifer Cameron
Melanie Palmisano Anil Chaturvedi Paula Inserra
Ansley Hammons Timothy Spencer
Tracy Beckel Liisa Oakes Janine Halama
Karen Lenzcyk Katherine Lohman Rachel Hanisch
David Martin Kathleen Dunlap Patricia Braly
Meg O’Brien Rebecca Clark Jeanne Dumestre